Breaking The Old 52 Week Low, DBV TECHNOLOGIE/S ADR (Nasdaq:DBVT) Closing At $16.53

DBV TECHNOLOGIE/S ADR (Nasdaq:DBVT)

November 14th, 2018
DBV TECHNOLOGIE/S ADR finished Tuesday’s trading session down 6.61%, a $1.17 decrease to close on $16.53. As well as the drop in value, DBV TECHNOLOGIE/S ADR hit a new 52 week low of $16.51, breaking the previous low of $16.65 from earlier this September. Despite the drop in value, trading volumes were solid at 217% of normal which can indicate investor opportunities. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

DBVT was outperformed by the rest of the Healthcare sector which went down only 0.68%.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending down. Financials saw the biggest increase of the day (0.59%), while Energy saw the biggest drop (2.39%). Healthcare has seen the biggest year-to-date gain at 10%. The biggest loss this year has been the Communication Services sector declining 12%.

Financials saw the biggest turnaround from its 5-day performance of -0.74%, as it went up 0.59%. Healthcare and Consumer Staples saw turn arounds from their five day positive performance, Healthcare with a drop of 0.68%.

Sector Breakdown

  • Financials went up with a 0.59% change.
  • Industrials went up with a 0.45% change.
  • Utilities went up with a 0.35% change.
  • Real Estate went up with a 0.14% change.
  • Information Technology went up with a 0.09% change.
  • Consumer Discretionary went down with a -0.03% change.
  • Communication Services went down with a -0.27% change.
  • Materials went down with a -0.29% change.
  • Consumer Staples went down with a -0.37% change.
  • Healthcare went down with a -0.68% change.
  • Energy went down with a -2.39% change.

DBV Technologies is based in Bagneux, France. DBV Technologies was founded in 2002.

DBV TECHNOLOGIE/S ADR Info

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (DBV TECHNOLOGIE/S ADR’s score is 2), and 9 is the best.

DBVT daily update

DBVT daily update
DBVT daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.